The therapeutic potential of tumour, 6.4 Gy to liver and 1.5 Gy to lung. The patient remained asymptomatic with no evidence of tumour 30 months from the start of treatment, whereas the remaining 7 patients exhibited tumour progression. The mean survival in CCA was 11.6 (SD 14.5) months. All 15 patients with HCC retained 131I with tumour: liver ratios of up to 30:1. The mean cumulative radiation dose was 34.7 (SD 32.4) Gy to tumour, 3.3 (SD 1.5) Gy to liver and 4.4 (SD 2.3) Gy to lung. The mean dose per administered activity was 3.8 (SD 4.1) cGy/MBq. Partial response (reduction in tumour size > 50%) was observed in 6 patients (40%). The mean survival was 7.1 (SD 6.0) months.
Liver retention of the labelled lipid was assessed by scintigraphy at 24-48 hours and 6-8 days using a Scintronix 480S Digicamera fitted with a high energy 1.9mm hexagonal-holed plane collimator. Planar anterior and posterior images of the liver and thorax were acquired over a five minute period and stored on floppy disk for later analysis. The pattern of uptake was compared to the distribution of Lipiodol within tumour tissue on synchronous CT scans of the liver and to 99Tc uptake on the pre-treatment colloid scan. Using the acquired images, regions of interest were drawn around the tumour, liver and lungs, and the total counts recorded for each region. Counts were also recorded over an equivalent area of low activity distant from the liver, and this "background" count subtracted from the tissue count in each case.
Three patients with HCC were scanned on an IGE Gemini 700 camera fitted with a 400KeV parallel-hole high resolution collimator, linked to a Saturn nuclear medicine computer for data acquisition and image processing. IGE software was used for tomographic image reconstruction and dosimetry. The doses of radioactivity administered to the tumour, surrounding liver and lung were calculated using a standard formulaeTM.
RESULTS

Cholangiocarcinoma
Localisation
Although prolonged retention of activity was observed in the peripheral liver parenchyma in patients with hilar tumours, a comparison of the scintigraphic and tomographic appearances 6-10 days after treatment showed no evidence of tumour-selective retention of the radio-isotope in any patient. However, diffuse retention was observed in one patient (Patient No. 07) who was reassessed 7 weeks following treatment and found to retain focal activity in the hilar mass ( Figure 1 The longest surviving patient has also shown evidence of disease progression clinically and has required readmission for recurrent obstructive jaundice, treated by segment III hepatico-jejunostomy. Although good localisation of the isotope was observed even in large, multifocal deposits the highest tumour: liver ratios were seen in patients with small discrete tumours. In one case tumour 1311 uptake was not confined to the liver. The patient (No. 19), a 41 year old man with a massive central hepatoma, received a small initial dose of isotope due to concern over poor liver function. Gamma imaging showed localisation within the liver but also demonstrated a small mediastinal nodule ( Figure 2a ). Five months later he remained well with no change in size of the tumour on CT scan and a second larger dose was administered. On this (Figure 4a ,b) and 3 months later a 5 cm wedge of liver containing 2 discrete tumour nodules was resected. Histological examination of the resected specimen showed both tumour nodules to be completely necrotic and surrounded by a zone of fibrotic but non-malignant parenchyma (Figure 4c ).
Five patients were alive and under regular follow-up at the end of the trial, having survived 4-19 months from the start of treatment. Eight patients died, two from widespread extrahepatic metastases and two from hepatic failure. Four patients died from tumour progression: all had extensive multifocal disease which had failed to respond to previous chemotherapy. Two patients were lost to followup, one of whom was in remission at 16 months. Survival in HCC, calculated by life-table analysis, was 61% at 6 months and 31% at 1 year ( Figure 5 ). The median (a) (b) (c) Figure 2 Intracardiac localisation of 131I. (a) Activity in mediastinal nodule (AP gamma scan at 48 hours) (b) Supra-diaphragmatic focus of activity (Oblique lateral CXR at 1 hour) (c) Activity in heart (AP gamma scan at 48 hours). To date there has been only one report on the use of 131I-Lipiodol in a case of intrahepatic cholangiocarcinomalS: no selective retention of the radio-isotope occurred. Targeted chemotherapy using an emulsion of Lipiodol with doxorubicin, in combination with stenting and long term systemic chemotherapy using mitozantrone, has been described in one case of cholangiocarcinoma19. The patient was reported to be alive and well 27 months following diagnosis. Our own experience in three cases treated with a Lipiodol-epirubicin emulsion has been disappointing, with a mean survival of 5.4 months from the start of treatment12. Systemic chemotherapy is rarely of benefit in cholangiocarcinoma, and whole liver irradiation is dose-limited to a maximum of 3500 rads by the low tolerance of normal liver tissue. However, the use of these modalities in combination with 131I Anti-CEA has been reported to increase both response rates and survival2. It is possible that a similar radical multimodal approach incorporating Lipiodol-targeted radiotherapy may provide an effective means of palliation in some patients with cholangiocarcinoma.
All fifteen patients with HCC showed tumour-specific retention of activity with tumour: liver dose ratios of up to 30:1. Previous investigators have found 131I-Lipiodol to be retained almost exclusively by the liver and lungs3. A measure of the accuracy of the dosimetry calculations used in this study can therefore be obtained from comparison of tissue activities with the administered activity, derived from the measured activity of the 31I-Lipiodol aliquot prior to injection minus the residual activity the end of the procedure. Calculation of the combined activities in tumour, liver and lung at time t 0 gave a median value of 87% of the estimated administered activity, with a range of 70 118%. Taking into account losses to other organs via the splanchnic circulation, and overestimation of the administered activity due to adherence of activity to the syringe and catheter, this is an acceptable accuracy for planar dosimetry. However, the accuracy of dosimetry based on planar scintigraphy is inferior to that achievable using the more sophisticated technique of SPECT imaging. For the last three cases in this series we had access to a tomographic gamma camera, which 
